Solid Biosciences reports Q2 net loss $25.1M; cash runway into Q2 2024; SGT-003 IND on track

Solid Biosciences Inc.

2022-Q2 EPS reported -$0.45

Net loss $25.1M in Q2 2022 vs $18.7M in Q2 2021; collaboration revenue $6.2M (up from $3.6M).
Cash and investments $162.9M as of June 30, 2022; estimated runway into Q2 2024.
Transition to transient transfection manufacturing for SGT-001; expects to continue dosing patients in 2023.
Next-gen candidate SGT-003 on track for mid-2023 IND submission; capsid shows improved muscle tropism vs AAV9.
Long-term data from IGNITE DMD trial of SGT-001 expected in early 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.